Missouri’s bioscience industry is an innovative and growing component of the overall U.S. economy. With a track record of generating high-quality jobs and steady growth, the bioscience industry has been a consistent engine for our economy and a key strength during past economic recessions. American innovation in bioscience helps support state and local communities in a variety of ways ranging from job creation, construction, tax revenues, and other economic impact values.

Driven by small-company innovators, the bioscience industry has also mobilized in an unprecedented manner to address the global COVID-19 pandemic, while continuing to develop other life-saving and life-enhancing products and services for the U.S. and the world. America’s bioscience industry as an innovator and economic driver has never been more important, both for our health and our economic stability.

Total Number of Facilities in Missouri 34
Jobs Directly Supported by the Industry in Missouri 35739
Annual Average Wage
Total Clinical Trials
Dollar Amount Invested in Clinical Trials
$354 Million
Clinical Trial Participants
Total Clinical Trial Economic Impact
$981.1 Million

View Facilities By District

District Total Facilities in District View Facilities in District
MO01 12 BASF Corp (A)

Bayer (H) (4)

Benson Hill Inc. (A)

CTC Genomics LLC (A)

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC (H)

M6P Therapeutics (H)

Mallinckrodt Pharmaceuticals (H)

Monsanto Company (A)

Monsanto Protein Technologies (A)

MO02 6 Bayer (H) (2)

National Corn Growers Association (O)

OnQuality Pharmaceuticals (H)

Pfizer Inc (H)

Sanofi Aventis US (H)

MO03 4 Cargill, Incorporated (A) (2)

Missouri Biotechnology Association (O)

Pfizer Global Research & Development (PGRD) (H)

MO04 1 Bayer (H)
MO05 1 Likarda, LLC (H)
MO06 8 BASF Corp (A) (2)

Bayer (H)

Boehringer Ingelheim Vetmedica (H)

Gevo Inc. (A)


Poet (A) (2)

MO07 1 Cargill, Incorporated (A)
MO08 1 Bayer (H)